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INTRODUCTION 
A novel coronavirus named SARS-CoV-2 has been identi-
fied as the causative agent of a global outbreak of respiratory 
tract disease, referred to as COVID-19 (1, 2). COVID-19 is char-
acterized by fever, cough, dyspnea and myalgia (2), but in 
some patients the infection results in moderate to severe 
acute respiratory distress syndrome (ARDS), requiring inva-
sive mechanical ventilation for a period of several weeks. 
COVID-19 patients may present with lymphopenia (2, 3), but 
the disease has also been associated with immune hyperre-
sponsiveness referred to as a ‘cytokine storm’ (4). A transient 
increase in co-expression of CD38 and HLA-DR by T cells, a 
phenotype of CD8+ T-cell activation in response to viral infec-
tion, was observed concomitantly (5). This increase in both 
CD4+ and CD8+ CD38+HLA-DR+ T cells preceded resolution of 
clinical symptoms in a non-severe, recovered, COVID-19 pa-
tient (6). 
Despite the large numbers of cases and deaths, there is 
limited information on the presence and phenotype of SARS-
CoV-2-specific T cells, especially in ARDS patients. Spike sur-
face glycoprotein (S)-, membrane (M)- and nucleoprotein 
(NP)-specific T cells were detected in PBMC from convales-
cent COVID-19 patients (7). More recently, Grifoni et al. re-
ported the presence of SARS-CoV-2-specific T cells in 
convalescent samples from predominantly mild COVID-19 
patients. They showed strong reactivity to the viral S and M 
proteins, and also strong CD4+ T-cell responses to N. Addi-
tionally, 8 other ORFs were targeted by both CD4+ and CD8+ 
T cells (8). Virus-specific T cells have also been detected after 
exposure to the related SARS-CoV and MERS-CoV, although 
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few studies have characterized cellular responses in human 
patients. For SARS-CoV-specific CD4+ T cells it was reported 
that the S glycoprotein accounted for nearly two-thirds of T-
cell reactivity, with N and M also accounting for limited re-
activity (9). For MERS-CoV-specific CD4+ T cells, responses 
targeting S, N and a pool of M and E peptides have been re-
ported (10). 
Here, we stimulated peripheral blood mononuclear cells 
(PBMC) from ten COVID-19 patients with ARDS, collected up 
to three weeks after admission to the intensive care unit 
(ICU), with MegaPools (MP) of overlapping or prediction-
based peptides covering the SARS-CoV-2 proteome (11). We 
detected SARS-CoV-2-specific CD4+ and CD8+ T cells in 10/10 
and 8/10 COVID-19 patients, respectively. Peptide stimula-
tion of healthy control (HC) age-matched PBMC samples col-
lected before the outbreak in most cases resulted in 
undetectable responses, although some potential cross-reac-
tivity due to infection with ‘common cold’ coronaviruses was 
observed. SARS-CoV-2-specific T cells predominantly pro-
duced effector and Th1 cytokines, although Th2 and Th17 cy-
tokines were also detected. 
 
RESULTS 
Patient characteristics 
We included ten COVID-19 patients with moderate to se-
vere ARDS in this study, and compared these to ten age-
matched HC. All patients were included in the study shortly 
after ICU admission; the duration of self-reported illness var-
ied between 5 and 14 days before inclusion (Fig. 1A). Patients 
were between 49 and 72 years old (average 58.9 ± 7.2 years) 
and of mixed gender (4 female, 6 male). HC were between 30 
and 66 years old (average 43 ± 13.6 years, not statistically dif-
ferent from the patient group) and of mixed gender (4 female, 
4 male, no data available for 2 donors). All patients tested 
SARS-CoV-2 positive by RT-PCR and were ventilated during 
their stay at the ICU. At the time of writing, 5 patients were 
transferred out of the ICU (case 1, 2, 4, 6 and 7), 3 patients 
were still in follow-up (case 5, 9 and 10), 1 patient was dis-
charged (case 8) and 1 patient was deceased (case 3). Case 4 
died 4 days after transfer out of the ICU. Patients were 
treated with lung protective ventilation using the higher 
PEEP/lower FiO2 table of the ARDSnet and restrictive volume 
resuscitation. They received antibiotics as a part of a treat-
ment regimen aimed at selective decontamination of the di-
gestive tract. Furthermore, all patients received chloroquine, 
lopinavir-ritonavir and/or corticosteroids for a brief period of 
time around admission to the ICU (Fig. 1A). 
COVID-19 ARDS patients present with lymphopenia 
Phenotyping analysis of PBMC collected 14 days post in-
clusion via flow cytometry indicated that COVID-19 patients 
presented with low percentages of CD3+ T cells in peripheral 
blood, corresponding to the previously reported lymphopenia 
(12.1 ± 8.7% in COVID-19 vs 44.3 ± 7.1% in HC, p<0.0001, Fig. 
1B) (2, 3). CD4:CD8 ratios were increased in COVID-19 pa-
tients when compared to HC (5.5 ± 3.0 in COVID-19 vs 2.3 ± 
0.9 in HC, p=0.0115, Fig. 1C). 
SARS-CoV-2 peptides and predicted epitopes 
PBMC from COVID-19 ARDS patients were stimulated 
with four different peptide MPs: MP_S, MP_CD4_R and two 
MP_CD8 pools. MP_S contained 221 overlapping peptides 
(15-mers overlapping by 10 amino acids) covering the entire 
S glycoprotein and can stimulate both CD4+ and CD8+ T cells. 
MP_CD4_R (R=remainder) contained 246 HLA class II pre-
dicted epitopes covering all viral proteins except S, specifi-
cally designed to activate CD4+ T cells. The two MP_CD8 
pools combined contained 628 HLA class I predicted epitopes 
covering all SARS-CoV-2 proteins, specifically designed to ac-
tivate CD8+ T cells (11). Results obtained with MP_CD8_A and 
MP_CD8_B have been concatenated and shown as a com-
bined stimulation named MP_CD8, but results obtained with 
separate stimuli are also shown. In addition to stimulation of 
PBMC from COVID-19 ARDS patients, PBMC from ten HC 
were tested in parallel. PBMC from healthy controls were ob-
tained before 2020 and could therefore not contain SARS-
CoV-2-specific T cells. However, they potentially contain 
cross-reactive T cells induced by circulating seasonal ‘com-
mon cold’ coronaviruses (12). 
Stimulation of PBMC collected 14 days post inclusion with 
the different peptide pools led to consistent detection of CD4+ 
and/or CD8+ SARS-CoV-2-specific T cells in COVID-19 ARDS 
patients (Fig. 2, Fig. 3). Specific activation of CD4+ and CD8+ 
T cells was measured via cell surface expression of CD69 and 
CD137; phenotyping of memory subsets was based on surface 
expression of CD45RA and CCR7 (Fig. S1). 
Characterization of SARS-CoV-2-specific CD4+ T cell re-
sponses 
Stimulation of PBMC with MP_S and MP_CD4_R led to 
consistent activation of SARS-CoV-2-specific CD4+ T cells 
(Fig. 2) in PBMC obtained from COVID-19 ARDS patients. 
Significant responses were detected when activation percent-
ages after stimulation with MP_S and MP_CD4_R were com-
pared with the vehicle control (DMSO). To allow comparison 
between HC and COVID-19 ARDS patients, we corrected the 
MP-specific activation percentages by subtracting the value 
obtained in the DMSO stimulation. Significant T-cell re-
sponses were observed in COVID-19 ARDS patients when 
compared with HC (0.64% in COVID-19 vs 0.02% in HC, 
p<0.0001 for MP_S and 0.29% in COVID-19 vs 0.02% in HC, 
p=0.0004 for MP_CD4_R, Fig. 2A and B, respectively). The 
stimulation index (SI) was calculated by dividing the MP-
specific responses by the DMSO responses, and donors with 
a SI > 3 were regarded responders (Fig. 4A). According to this 
definition all COVID-19 ARDS patients responded to the 
MP_S and MP_CD4_R pools, whereas 1/10 and 2/10 of the HC 
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responded, respectively (Fig. 7). Overall, the MP_S peptide 
pool induced stronger responses than the MP_CD4_R pep-
tide pool, indicating that the S glycoprotein is a strong in-
ducer of CD4+ T-cell responses. Phenotyping of 
CD4+CD69+CD137+ activated T cells identified the majority of 
these SARS-CoV-2-specific T cells as central memory T cells, 
based on CD45RA and CCR7 expression (TCM). TCM express 
homing receptors required for extravasation and migration 
to secondary lymphoid tissues, but also have high prolifera-
tive capacity with low dependence on co-stimulation (13, 14). 
Characterization of SARS-CoV-2-specific CD8+ T cell re-
sponses 
SARS-CoV-2-specific CD8+ T cells were activated by both 
the MP_S and MP_CD8 peptide pools when compared to ve-
hicle control (Fig. 3A and B). Mainly the peptides pooled in 
MP_CD8_A were responsible for this activation (Fig. 3C and 
D). Furthermore, significant responses were detected when 
activation percentages after stimulation with MP_S and 
MP_CD8 were compared between HC controls and COVID-19 
ARDS patients after DMSO correction (0.90% in COVID-19 vs 
0.03% in HC, p=0.0003 for MP_S and 0.57% in COVID-19 vs 
0.03% in HC, p<0.0001 for MP_CD8, Fig. 3A and B). In addi-
tion to inducing specific CD4+ T cells, the S glycoprotein also 
induced CD8+ T cell responses. Calculation of the SI identi-
fied 8/10 and 4/9 (not enough cells were obtained for 
MP_CD8 stimulation for 1 donor) of the COVID-19 ARDS pa-
tients as responders to MP_S and MP_CD8, respectively, 
whereas 1/10 of the HC responded to the MP_S stimulation 
(Fig. 4B, C and 7). Phenotyping of CD8+CD69+CD137+ acti-
vated T cells showed that these had a mixed phenotype. The 
majority of virus-specific CD8+ T cells was identified as CCR7- 
effector memory (TEM) or terminally differentiated effector 
(TEMRA) (13). Both these CD8+ effector subsets are potent pro-
ducers of IFN-γ, contain preformed perforin granules for im-
mediate antigen-specific cytotoxicity and home efficiently to 
peripheral lymphoid tissues (14, 15). 
Cytokine profiles after antigen-specific stimulation 
As production of pro-inflammatory cytokines can be pre-
dictive of clinical outcome for other viral diseases (16), we 
measured antigen-specific production of 13 cytokines in cell 
culture supernatants from PBMC after stimulation. The same 
samples as shown in Fig. 1-4 were included in this analysis, 
using samples obtained 14 days after ICU admission. PBMC 
were stimulated with the respective peptide pools, cytokine 
production after MP_S stimulation is shown in Fig. 5 and Fig. 
S2 as representative data. When compared to the vehicle con-
trol stimulation, PBMC obtained from COVID-19 ARDS pa-
tients specifically produced IFN-γ, TNF-α, IL-2, IL-5, IL-13, 
IL-10, IL-9, IL-17A, IL-17F and IL-22 after MP_S stimulation 
(Fig. 5, Fig. S2). 
When comparing COVID-19 ARDS patients with HC, stim-
ulation of PBMC by the overlapping S peptide pool led to a 
strong significant production of the Th1 or effector cytokines 
IFN-γ, TNF-α and IL-2 in COVID-19 ARDS patients. More 
characteristic Th2 cytokines (IL-5, IL-13, IL-9 and IL-10) were 
also consistently detected, albeit at low levels. IL-4 and IL-21 
could not be detected at all. IL-6 levels were not different be-
tween COVID-19 patients and HC. However, these results 
were difficult to interpret because mock stimulation already 
resulted in high IL-6 expression. Antigen-specific production 
of cytokines related to a Th17 response was also consistently 
detected; PBMC from COVID-19 ARDS patients produced sig-
nificantly more IL-17A, IL-17F and IL-22 than HC. 
In general, stimulation of PBMC from COVID-19 ARDS 
patients with MP led to a dominant production Th1 or effec-
tor cytokines (IFN-γ, TNF-α, IL-2), but Th2 (IL-5, IL-13, IL-9, 
IL-10) and Th17 (IL-17A, IL-17F and IL-22) cytokines could 
also be detected. Although not enough COVID-19 ARDS pa-
tients were included in this study to correlate specific T cell 
responses to clinical outcome, we did observe differences in 
cytokine production profiles on a case-per-case basis (Fig. 
S2D). Plotting the respective cytokine quantities as a percent-
age of total cytokine production showed that either IL-6 (case 
3, 5 and 9), TNF-α (case 1, 3 and 9), IL-2 (case 8) or IFN-γ 
(case 2, 4, 6, 7 and 10) dominated the response. 
Longitudinal detection of SARS-CoV-2-specific T-cell 
responses 
Finally, we studied the kinetics of development of virus-
specific humoral and cellular immune responses in COVID-
19 ARDS patients included in this study. Real time RT-PCR 
detection of SARS-CoV-2 genomes in respiratory tract sam-
ples showed a decreasing trend over time (Fig. 6A, ANOVA 
repeated measures p<0.001), whereas virus-specific serum 
IgG antibody levels, measured by RBD ELISA, showed a sig-
nificant increase (Fig. 6B, ANOVA repeated measures, 
p<0.001). Concomitantly, SARS-CoV-2-specific CD4+ and 
CD8+ T cells were detected in all patients at multiple time 
points. For CD4+ T cell responses, the frequencies of virus-
specific responder cells increased significantly over time (Fig. 
6C, ANOVA repeated measures, p<0.001), for CD8+ T cells this 
increase was not as apparent (Fig. 6D, ANOVA repeated 
measures, p=0.1001). We found evidence for a direct negative 
correlation between viral loads and IgG ELISA (r=0.6630, 
p<0.0001) and viral loads and CD4+ Tcells (r=0.5675, 
p=0.0007), and a positive correlation between the appearance 
of IgG antibodies and virus-specific T cells (r=0.6360, 
p=0.0002) (Fig. S3). 
 
DISCUSSION 
Collectively, these data provide information on the phe-
notype, breadth and kinetics of virus-specific cellular im-
mune responses in COVID-19 ARDS patients. We provide 
evidence that SARS-CoV-2-specific CD4+ and CD8+ T cells ap-
pear in blood of ARDS patients in the first two weeks post 
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onset of symptoms. It is important to mention that this study 
focused on PBMC samples, but tissue-resident T cells un-
doubtedly play an important role in this early response. 
SARS-CoV-2-specific CD4+ T cells in blood typically had a cen-
tral memory phenotype, whereas CD8+ T cells had a more ef-
fector phenotype. Peng et al. also identified HLA-B*40:01-
restricted T cells with mainly a central and effector memory 
phenotype (17). Consistent production in response to viral an-
tigen of IFN-γ, TNF-α, IL-2, IL-5, IL-13, IL-9, IL-10, IL-17A, IL-
17F and IL-22 was observed, with a dominant production of 
the effector and Th1 cytokines. Due to limitations in the num-
ber of PBMC that could be obtained from severe COVID-19 
ARDS patients in an ICU setting, we could not resolve which 
cells were responsible for production of which cytokine by 
intracellular cytokine staining. 
Elevated levels of IL-6 in patient plasma have been corre-
lated to respiratory failure in COVID-19 patients (18). Alt-
hough we could not detect increased specific production of 
IL-6 in PBMC stimulated with peptide pools due to high back-
ground production in controls, we detected a dominant IL-6 
and TNF-α response in cell culture supernatants from the pa-
tient deceased due to respiratory failure (case 3, Fig. S2D). To 
determine the role of T cells in COVID-19, it is crucial that 
the cell types responsible for the production of IL-6 and the 
concomitant ‘cytokine storm’ are identified in large compar-
ative cohort studies. 
We included PBMC obtained from ten buffy coats ob-
tained before the SARS-CoV-2 pandemic as negative HC. 
These HC were similar to the studied COVID-19 ARDS pa-
tients regarding age and gender. In some instances, reactive 
T cells were detected in HC after MP stimulation, both on 
basis of T-cell activation and cytokine production (Fig. 4, 6 
and 7). Since PBMC from these HC could not contain SARS-
CoV-2-specific T cells, we hypothesize that these responses 
were cross-reactive and had been induced by circulating sea-
sonal ‘common cold’ coronaviruses. If we consider samples 
with a SI > 3 as responders, we identified 2 out of 10 HC (20%) 
to have these cross-reactive T cells. Our study reports re-
sponses in unexposed individuals in the Netherlands. This 
fits well with the report of Grifoni et al. from the USA (8) and 
from Braun et al. from Germany (19), Le Bert et al. from Sin-
gapore (20), and Meckiff et al. from the UK (21), who all re-
port significant rates of reactivity from unexposed subjects. 
Interestingly, Peng et al. did not see significant responses po-
tentially reflecting geographical and temporal variations, or 
the importance of experimental conditions (17). It is possible 
that HLA genotypes influence these responses, as well as the 
SARS-CoV-2-responses that were detected in ARDS patients. 
This is a topic that merits further investigation. The role of 
preexisting SARS-CoV-2-reactive T cells as a correlate of pro-
tection or pathology is unclear, and needs to be addressed in 
prospective studies. 
Novel SARS-CoV-2 vaccines are currently in development 
and mainly focus on the surface glycoprotein S as an antigen 
for efficient induction of virus-specific neutralizing antibod-
ies. We now show that S can also be a potent immunogen for 
inducing virus-specific CD4+ and CD8+ T cells. This is in good 
concordance with publications on related coronaviruses 
SARS-CoV and MERS-CoV (9, 10), and also with recent re-
ports detecting SARS-CoV-2-specific T cell responses (7, 8, 17, 
19, 22, 23). Our study adds to that body of literature, as we 
specifically studied a well-defined ARDS patient cohort and 
studied samples longitudinally, while correlating these to vi-
ral loads, humoral responses, memory phenotypes and cyto-
kine response profiles. 
Here, we specifically studied T-cell responses in ARDS pa-
tients admitted to the ICU. By definition these are all severe 
COVID-19 patients, therefore we cannot draw any conclu-
sions on how the T-cell responses relate to disease severity. 
Whether presence and certain phenotypes of T cells are cor-
related to a ‘good’ or ‘bad’ prognosis remains to be deter-
mined. Collectively, these data shed light on the potential 
variations in T-cell responses as a function of disease severity, 
an issue that is key to understanding the potential role of im-
munopathology in the disease, as well as to inform vaccine 
design and evaluation. 
 
MATERIALS AND METHODS 
Study design 
Here, we set out to detect and characterize SARS-CoV-2-
specific CD4+ and CD8+ T-cell responses in longitudinal 
PBMC samples obtained from COVID-19 ARDS patients. The 
patient cohort was well-characterized, including ten patients, 
and defined by a positive RT-PCR on a sample from the res-
piratory tract. From each patient, samples at multiple time 
points (day 0, 7, 14 and later if available) were tested. These 
patients were directly compared with ten HC. 
This study relied on the use of pre-designed peptide MP 
containing overlapping peptides or predicted epitopes for 
stimulation of PBMC. T-cell activation and phenotype were 
determined by flow cytometry, whereas cytokine production 
was determined by a beads-based multiplex assay. Each stim-
ulation assay consisted of 8 conditions: stimulation with 4 
different MP, a negative DMSO control, a negative medium 
control, a positive PHA control and a CMV control. A sample 
nonresponsive to PHA stimulation would have been excluded 
from analysis (0 occurrences); all other data was included. 
Due to the limited nature of the material (PBMC from ARDS 
patients), activation after stimulation was measured in single 
determinations. All raw data obtained is provided in tabular 
format in Table S1. 
Ethical statement 
Patients admitted into the intensive care unit (ICU) with 
Acute Respiratory Distress Syndrome (ARDS) resulting from 
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SARS-CoV-2 infection at Erasmus MC, Rotterdam, the Neth-
erlands were included in a biorepository study aimed at 
ARDS and sepsis in the ICU. The first EDTA blood samples 
for PBMC isolation were obtained no more than 2 days after 
admission into the Erasmus MC ICU. Samples were collected 
weekly until a final sample at 28 days post study inclusion or 
for as long as the patient was in the ICU. Patient care and 
research were conducted in compliance within guidelines of 
the Erasmus MC and the Declaration of Helsinki. Due to the 
clinical state of most ARDS patients (i.e. intubated, coma-
tose), deferred proxy consent was obtained instead of direct 
written informed consent from the patients themselves. Ret-
rospective written informed consent was obtained from pa-
tients after recovery. The study protocol was approved by the 
medical ethical committee of Erasmus MC, Rotterdam, the 
Netherlands (MEC-2017-417 and MEC-2020-0222). Healthy 
control (HC) human buffy coats were requested as a compar-
ator group at the Sanquin Blood Bank (Rotterdam, the Neth-
erlands); written informed consent for research use was 
obtained. HCs were slightly younger than the included 
COVID-19 patients, however this was a non-significant differ-
ence and we therefore consider the HC and COVID-19 pa-
tients age-matched. 
Diagnosis 
Real-time RT-PCR on the E-gene was performed as de-
scribed previously (24) on RNA isolated from sputa, nasopha-
ryngeal or oropharyngeal swabs by MagnaPure (Roche 
Diagnostics, The Netherlands) using the total nucleic acid 
(TNA) isolation kit. 
PBMC isolation 
PBMC were isolated from EDTA blood samples. Tubes 
were centrifuged at 200g for 15 min to separate cellular parts. 
The plasma-containing fraction was collected, centrifuged at 
1200g for 15 min, and the plasma was aliquoted and stored at 
-20°C. The cellular fraction was reconstituted with phos-
phate-buffered saline (PBS) and subjected to Ficoll density 
gradient centrifugation (500g, 30min). PBMC were washed 
and frozen in 90% fetal bovine serum (FBS) and 10% dimethyl 
sulfoxide (DMSO, Sigma Life Science) at -135°C. Upon use, 
PBMC were thawed in IMDM (Lonza, Belgium) supple-
mented with 10% FBS, 100 IU of penicillin/ml, 100 μg of 
streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine 
(Lonza, Belgium) (I10F medium). PBMC were treated with 50 
U/ml Benzonase (Merck) for 30 min at 37°C prior to use in 
stimulation assays. 
Epitope MegaPool (MP) design and preparation 
SARS-CoV-2 virus-specific CD4 and CD8 peptides were 
synthesized as crude material (A&A, San Diego, CA), resus-
pended in DMSO, pooled and sequentially lyophilized as pre-
viously reported (25). SARS-CoV-2 epitopes were predicted 
using the protein sequences derived from the SARS-CoV-2 
reference sequence (GenBank: MN908947) and IEDB 
analysis-resource as previously described (11, 26). Specifically, 
CD4 SARS-CoV-2 epitope prediction was carried out using a 
previously described approach in Tepitool resource in IEDB 
(27, 28) similarly to what was previously described (11), but 
removing the resulting Spike glycoprotein epitopes from this 
prediction (CD4-R(remainder) MP, n=246). To investigate in 
depth Spike-specific CD4+ T cells, overlapping 15-mer by 10 
amino acids have been synthesized and pooled separately 
(CD-4 S(spike) MP, n=221). CD8 SARS-CoV-2 epitope predic-
tion was performed as previously reported, using the 
NetMHCpan4.0 algorithm for the top 12 more frequent HLA 
alleles in the population (HLA-A*01:01, HLA-A*02:01, HLA-
A*03:01, HLA-A*11:01, HLA-A*23:01, HLA-A*24:02, HLA-
B*07:02, HLA-B*08:01, HLA-B*35:01, HLA-B*40:01, HLA-
B*44:02, HLA-B*44:03) and selecting the top 1 percentile pre-
dicted epitopes per HLA allele (11). The 628 predicted CD8 
epitopes were split in two CD8 MPs containing 314 peptides 
each. 
SARS-CoV-2 RBD ELISA 
Serum or plasma samples were analyzed for the presence 
of SARS-CoV-2 specific antibody responses using a validated 
in-house SARS-CoV-2 receptor binding domain (RBD) IgG 
ELISA as previously described (29). Briefly, ELISA plates 
were coated with recombinant SARS-CoV-2 RBD protein. Fol-
lowing blocking, samples were added and incubated for 1 
hour, after which the plates were washed and a secondary 
HRP-labeled rabbit anti-human IgG (DAKO) was added. Fol-
lowing a one hour incubation, the plates were washed, the 
signal was developed using TMB, and the OD450 was meas-
ured for each well. All samples reported here were interro-
gated for the presence of antibodies on the same plate. 
Ex vivo stimulations 
PBMC were plated in 96-wells U bottom plates at 1 × 106 
PBMC per well in RPMI1640 (Lonza, Belgium) supplemented 
with 10% human serum, 100 IU of penicillin/ml, 100 μg of 
streptomycin/ml (Lonza, Belgium) and 2 mM L-glutamine 
(Lonza, Belgium) (R10H medium) and subsequently stimu-
lated with the described CD4 and CD8 SARS-CoV-2 MPs at 
1μg/ml. A stimulation with an equimolar amount of DMSO 
was performed as negative control, phytohemagglutinin 
(PHA, Roche, 1μg/ml) and stimulation with a combined CD4 
and CD8 cytomegalovirus MP (CMV, 1μg/ml) were included 
as positive controls. Twenty hours after stimulation cells 
were stained for detection of activation induced markers and 
subjected to flow cytometry. Supernatants were harvested for 
multiplex detection of cytokines. 
Flow cytometry 
Activation-induced markers were quantified via flow cy-
tometry (FACSLyric, BD Biosciences). A surface staining on 
PBMC was performed with anti-CD3PerCP (BD, clone SK7), 
anti-CD4V450 (BD, clone L200), anti-CD8FITC (DAKO, clone 
DK25), anti-CD45RAPE-Cy7 (BD, clone L48), anti-CCR7APC (R&D 
First release: 26 June 2020  immunology.sciencemag.org  (Page numbers not final at time of first release) 6 
 
Systems, clone 150503), anti-CD69APC-H7 (BD, clone FN50) and 
anti-CD137PE (Miltenyi, clone 4B4-1). T-cell subsets were iden-
tified via the following gating strategy: LIVE CD3+ were se-
lected and divided in CD3+CD4+ and CD3+CD8+. Within the 
CD4 and CD8 subsets, memory subsets were gated as 
CD45RA+CCR7+ (naive, TN), CD45RA-, CCR7+ (central 
memory, TCM), CD45RA-CCR7- (effector memory, TEM) or 
CD45RA+CCR7- (terminally differentiated effectors, TEMRA). T 
cells specifically activated by SARS-CoV-2 were identified by 
up-regulation of CD69 and CD137. An average of 500,000 
cells was always acquired, the gating strategy is schematically 
represented in (Fig. S1A-J). In analysis, PBMC stimulated 
with MP_CD8_A and MP_CD8_B were concatenated and an-
alyzed as a single file for SARS-CoV-2-specific responses to 
MP_CD8. 
Multiplex detection of cytokines 
Cytokines in cell culture supernatants from ex vivo stim-
ulations were quantified using a human Th cytokine panel 
(13-plex) kit (LEGENDplex, Biolegend). Briefly, cell culture 
supernatants were mixed with beads coated with capture an-
tibodies specific for IL-5, IL-13, IL-2, IL-6, IL-9, IL-10, IFN-γ, 
TNF-α, IL-17A, IL-17F, IL-4, IL-21 and IL-22 and incubated for 
2 hours. Beads were washed and incubated with biotin-la-
beled detection antibodies for 1 hour, followed by a final in-
cubation with streptavidinPE. Beads were analyzed by flow 
cytometry. Analysis was performed using the LEGENDplex 
analysis software v8.0, which distinguishes between the 13 
different analytes on basis of bead size and internal dye. 
Quantity of each respective cytokine is calculated on basis of 
intensity of the streptavidinPE signal and a freshly prepared 
standard curve. 
Statistical analysis 
For comparison of CD3+ T cell percentages, CD4:CD8 ra-
tios, CD69+CD137+ stimulated T cells and cytokine levels be-
tween HC and COVID-19 patients, all log transformed data 
was tested for normal distribution. If distributed normally, 
groups were compared via an unpaired t test. If not distrib-
uted normally, groups were compared via a Mann-Whitney 
test. Comparisons between different stimulations (DMSO 
versus MP) were performed by paired t test (normal distribu-
tion) or Wilcoxon rank test (no normal distribution). Two-
tailed p values are reported throughout the manuscript. One-
way ANOVA repeated measures was used to test for increas-
ing or decreasing trends over sequential time points (0, 7 and 
14 days post inclusion). 
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Figure S1. Flow cytometry gating strategy. 
Figure S2. SARS-CoV-2-specific cytokine production in COVID-19 ARDS patients. 
Figure S3. Correlations between kinetics of viral loads, virus-specific antibodies and 
virus-specific T cell responses. 
Table S1. Raw data (in Excel spreadsheet). 
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Fig. 1. Clinical overview of moderate to severe COVID-19 ARDS patients. (A) Onset of symptoms, hospitalization 
status, treatment and follow-up of n=10 COVID-19 ARDS patients included in this study. PBMC samples were obtained 
weekly after admission to the study. Symbols shown next to the cases match throughout all figures. (B) Percentages 
of CD3+ T cells within the total LIVE gate measured by flow cytometry performed on PBMC collected 14 days post 
inclusion. (C) CD4:CD8 ratios measured by flow cytometry performed on PBMC collected 14 days post inclusion. 
Panels b and c show individual values for n=10 patients versus n=10 HC, as well as the mean ± SD. Asterisk denotes a 
significant difference. HC = healthy control. 
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Fig. 2. SARS-CoV-2-specific CD4+ T-cell responses in COVID-19 ARDS patients. (A, B) Antigen-specific 
activation of CD4+ T cells after stimulation for 20 hours with MP_S (A) and MP_CD4_R (B), measured via cell 
surface expression of CD69 and CD137 (gating in Fig. S1). Two left panels show activation percentages (within 
CD3+CD4+) obtained with the vehicle control (DMSO) and specific stimulation (MP) for HC and COVID-19 patients. 
The third panel shows the specific activation percentages corrected by subtracting the background present in the 
DMSO stimulation to allow comparison of both groups. The fourth panel shows the memory phenotype of the 
CD69+CD137+ responder cells in a donut diagram. Panels show individual values for n=10 patients versus n=10 
HC, as well as the mean ± SD. Asterisk denotes a significant difference. HC = healthy control. Symbol shapes of 
COVID-19 patients are identical between panels, and refer back to Fig. 1. 
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Fig. 3. SARS-CoV-2-
specific CD8+ T-cell 
responses in COVID-19 
ARDS patients. (A, B, C, D) 
Antigen-specific activation 
of CD8+ T cells after 
stimulation for 20 hours 
with MP_S (A), MP_CD8_A 
(C), and MP_CD8_B, 
measured via cell surface 
expression of CD69 and 
CD137 (gating in Fig. S1). 
MP_CD8 panels (B) show 
the concatenated 
responses from panels C 
and D. Two left panels show 
activation percentages 
(within CD3+CD8+ gate) 
obtained with the vehicle 
control (DMSO) and 
specific stimulation (MP) 
for HC and COVID-19 
patients. The third panel 
shows the specific 
activation percentages 
corrected by subtracting 
the background present in 
the DMSO stimulation to 
allow comparison of both 
groups. The fourth panel 
shows the memory 
phenotype of the 
CD69+CD137+ responder 
cells in a donut diagram. 
Panels show individual 
values for n=10 patients 
versus n=10 HC, as well as 
the mean ± SD. Asterisk 
denotes a significant 
difference. HC = healthy 
control. Symbol shapes of 
COVID-19 patients are 
identical between panels, 
and refer back to Fig. 1.. 
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Fig. 4. Stimulation index 
identifies specific 
responders. Antigen-specific 
activation of CD4+ (A) and 
CD8+ T cells (B,C) in COVID-19 
patients after stimulation for 
20 hours with peptide 
MegaPools (MP) shown as 
stimulation index (SI). 
Stimulation index is derived by 
dividing the percentage 
obtained with specific 
stimulation (MP) by the 
percentage obtained with the 
vehicle control (DMSO). Values 
for respective stimulations are 
shown in Fig. 2 (CD4+, color 
coded in blue) and Fig. 3 (CD8+, 
color coded in red). Donors 
with a SI > 3 (dotted line) are 
regarded as responders to MP 
stimulation. Panels show 
individual values for n=10 
patients vs. n=10 HC, as well as 
the mean ± SD. Asterisk 
denotes a significant 
difference. HC = healthy 
control. Symbol shapes of 
COVID-19 patients are identical 
between panels, and refer back 
to Fig. 1. 
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Fig. 5. SARS-CoV-2-
specific cytokine 
production in COVID-
19 ARDS patients. (A-
J) Antigen-specific 
production of cytokines 
measured in cell culture 
supernatants from 
PBMC obtained 14 days 
post ICU admission 
stimulated (20 hours) 
with MP_S. Two left 
panels show quantities 
obtained with the 
vehicle control (DMSO) 
and specific stimulation 
(MP) for HC and 
COVID-19 patients. The 
third panel shows the 
quantity corrected by 
subtracting the 
background present in 
the DMSO stimulation 
to allow comparison of 
both groups. Panels 
show individual values 
for n=10 patients 
versus n=10 HC, as well 
as the geometric mean. 
Asterisk denotes a 
significant difference. 
HC = healthy control. 
Additional cytokines 
(IL-4, IL-17F and IL-21) 
are shown in Fig. S2. 
Symbol shapes of 
COVID-19 patients are 
identical between 
panels, and refer back 
to Fig. 1. 
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Fig. 6. SARS-CoV-2 replication and humoral and cellular immune response kinetics in COVID-19 
ARDS patients. (A, B, C, D) Sequential measurements of SARS-CoV-2 genomes detected in upper 
respiratory tract samples by real-time RT-PCR (40-ct, A), SARS-CoV-2-specific serum RBD IgG 
antibody levels detected by ELISA (OD450, B) and percentage SARS-CoV-2-specific CD4+ and CD8+ 
T cells after MP_S stimulation of PBMC (C, D), plotted against days post onset of symptoms. Genome 
levels showed a significant decrease over time, antibody levels and specific CD4+ T-cell frequencies 
significantly increased (p<0.001, ANOVA repeated measures). A specific increase or decrease of 
specific CD8+ T cells over time was not detected (p=0.1001, ANOVA repeated measures). Symbol 
shapes of COVID-19 patients are identical between panels, and refer back to Fig. 1. 
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Fig. 7. Expression of activation markers in representative samples. (A, B, C) Representative activation 
plots showing CD69 and CD137 up-regulation from a non-responder HC (A), cross-reactive HC (B) and 
reactive COVID-19 sample (C). Each panel shows activation after stimulation with DMSO (negative control) 
or MP_S. Top row shows CD4+ T cell responses, bottom row shows CD8+ T cell responses. Percentages 
indicate activated CD69+CD137+ cells as a fraction of either CD4+ or CD8+ T cells. 
